Pneumococcal Vaccines Market - Forecasts from 2022 to 2027

The global pneumococcal vaccines market is projected to witness a CAGR of 6.97% during the forecast period to reach a market size of US$15.963 billion by 2027, increasing from US$9.962 billion in 2020.

Introduction

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Immunization is one of the widely accepted forms against the disease.

Market Drivers.

Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to children under two years and adults 65 years and older. The regular vaccination programs under the national policy are aiding the market to grow. Secondly, the rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the expansion of the market in the current scenario.

By type, the pneumococcal conjugate vaccine segment is the most significant contributor to the global pneumonia vaccine market and is expected to maintain its dominant position throughout the analysis period. Geographically, the Asia-Pacific region showcases the highest growth potential due to changing health sectors and efforts led by the international organization, while North America continues to dominate the market.

Growth Factors.

• Growing incidence of childhood pneumonia.

Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children. The South Asian region has the highest incidence with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates which is expanding the vaccines market to increase its production capacity and spread its reach.

• Raising awareness and policies.

International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to bring down the pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases. As such, the government of India launched 2017 the pneumococcal conjugate vaccine (PCV) into its national immunization program. These plans and policies boast the vaccines market with novel products being introduced and expansion of the existing product portfolios.

Restraints.

The high cost involved in the production of vaccines and the long duration of the process of production is challenging factors for market growth. However, the government subsidies on vaccine production and funds released by international organizations are helping to clear the hindrances of the path.

Impact of COVID-19 on the Pneumococcal Vaccines Market

The pandemic had an unforeseen effect on the vaccination market, and the impact on the pneumococcal vaccine market is no different. At first, routine vaccination decreased due to the pandemic. However, later studies indicated that the COVID-19 pandemic increased the need for pneumococcal vaccination, causing shipping restrictions on pneumococcal vaccines, which may cause a shortage of vaccines during a pandemic.

Competitive Insights.

The market leaders for the Global Pneumococcal Vaccines Market are Pfizer, GSK, Merck Serum Institute of India Pvt Ltd, and AstraZeneca. The recent developments by the key players include:

• In 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) approved their pneumonia vaccine named PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). The vaccine was developed by Pfizer for adults ages 18 years and older in order to help the body fight pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes.
• Merck's pneumonia vaccine called VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), which was specifically developed for adults 18 years of age and older to help the body fight Streptococcus pneumoniae serotypes, got the approval of the U.S. Food and Drug Administration (FDA)
• In 2020, Serum Institute announced it had developed a pneumonia vaccine named PNEUMOSIL by collaborating with PATH and Bill and Melinda Gates Foundation for more than a decade.

Segmentation:

• By Type

Conjugate vaccines

Polysaccharide vaccines

• By Application

Routine Vaccination

Vaccination for Disease/ Infection

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• Germany
• France
• Italy
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• Japan
• China
• India
• Indonesia
• Taiwan
• Thailand
• Others